Document is current
Any future updates will be listed below
-
Authors
Tuazon, Sherilyn A. https://orcid.org/0000-0002-6702-9057
Sandmaier, Brenda M.
Gooley, Theodore A.
Fisher, Darrell R.
Holmberg, Leona A.
Becker, Pamela S. https://orcid.org/0000-0001-6235-9463
Lundberg, Sally J.
Orozco, Johnnie J.
Gopal, Ajay K.
Till, Brian G. https://orcid.org/0000-0002-4718-8288
Coffey, David G.
Nartea, Margaret E.
Matesan, Manuela C.
Pagel, John M. https://orcid.org/0000-0001-5745-8125
Rajendran, Joseph G.
Press, Oliver W.
Bensinger, William I.
Green, Damian J. https://orcid.org/0000-0003-0477-1446
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205248, P30 CA015704, P30 CA015704, P30 CA015704, P30 CA015704, R21 CA155911)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 6 April 2020
Revised: 12 June 2020
Accepted: 14 July 2020
First Online: 24 July 2020
Compliance with ethical standards
:
: BMS reports consulting for Kiadis Pharma, Actinium Pharmaceuticals, Frazier Healthcare Ventures, and Bristol-Meyers Squibb, equity ownership in AnaptysBio, Oncoresponse, Inipharm, EpiThany, and Blaze Bioscience, employment and equity ownership in Mavupharma, Inc., and research funding from Bellicum. LAH reports research funding from Seattle Genetics, Merck, Millennium Pharmaceuticals, Celgene, Sanofi-Aventis, royalties from UpToDate, and consulting for Jazz Pharmaceuticals and the National Comprehensive Cancer Network. JJO receives research funding from Actinium Pharmaceuticals. AKG reports grants and nonfinancial research support from Teva, Bristol-Myers Squibb, Merck, Takeda, Seattle Genetics, Pfizer, Janssen, Takeda, and Effector, and personal fees and nonfinancial support from Seattle Genetics, Pfizer, Janssen, Gilead Sciences, Sanofi-Aventis, Spectrum, Amgen, Aptevo, BRIM bio, Acerta, I-Mab-pharma, Compliment, Asana Bio, and Incyte. BGT holds patents and receives royalties and research funding from Mustang Bio. JMP reports consulting for Actinium Pharmaceuticals, Astrazeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, F. Hoffman-La Roche, Pharmacyclics LLC, Teva Pharmaceuticals, consulting and personal fees from Celgene, Gilead Sciences, Janssen, personal fees from Millennium Pharmaceuticals, and honoraria from Seattle Genetics and Spectrum Pharmaceuticals. WIB reports consulting and personal fees from Amgen, Celgene, Janssen and personal fees from Millennium Pharmaceuticals. DJG receives research funding from Juno Therapeutics, Celgene, Merck, Seattle Genetics, Sanofi-Aventis, Cellectar Bio and consults for Cellectar Bio, Celgene, Seattle Genetics, and GSK. The remaining authors have disclosed no conflicts of interest.
